|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
|
|---|---|---|---|---|---|---|
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | ||||||
| Short-term investments | ||||||
| Prepaid expenses | ||||||
| Other current assets | ||||||
| Total current assets | ||||||
| Property and equipment, net | ||||||
| Restricted cash | ||||||
| Other assets | ||||||
| Total assets | ||||||
| Liabilities and shareholders' deficit | ||||||
| Current liabilities: | ||||||
| Accounts payable | ||||||
| Clinical trial accrual | ||||||
| Accrued liabilities | ||||||
| Current portion of long term debt | ||||||
| Current portion of capital lease obligation | ||||||
| Total current liabilities | ||||||
| Deferred rent | ||||||
| Lease incentive | ||||||
| Capital lease obligation | ||||||
| Long-term debt, net of discount | ||||||
| Total liabilities | ||||||
| Convertible preferred stock | ||||||
| Series A Preferred Stock | ||||||
| Total convertible preferred stock | ||||||
| Shareholders' equity (deficit): | ||||||
| Common stock, par $0.001; 250,000,000 shares authorized at September 30, 2015 and December 31, 2014; 25,236,032 and 20,898,212 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively | ||||||
| Additional paid-in capital | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total shareholders' equity (deficit) | ||||||
| Accumulated other comprehensive income (loss) | ||||||
| Total shareholders' equity | ||||||
| Total liabilities and shareholders' equity |
Loading...
